The TB Alliance opened 2003 with an expanded portfolio of drug candidates and projects. A number of projects are now underway to upgrade the tools of drug development and expedite the progress of early portfolio investments.
Recent highlights include a major project to improve clinical trial expertise in Africa and Asia with the International Union Against TB and Lung Disease, a leading animal model facility at Johns Hopkins, and a new anti-tuberculosis compound developed by researchers at Wellesley College. In addition, PA-824 continues to move into the next phases of development, a process managed with the support of Research Triangle Institute (RTI).
Our current partners include:
- Johns Hopkins University
- International Union Against Tuberculosis & Lung Disease
- National Institutes of Health (U.S.)
- Research Triangle Institute
- Stanford Research Institute
- Wellesley College
The Alliance is also in the process of reviewing several other drug candidates, including several from industry. After extensive consultation with the Scientific Advisory Committee, the Alliance is preparing to announce a new Request for Proposals this Spring. Stay posted.